摘要
神经元一氧化氮合酶(nNOS)生成关键信号递质一氧化氮(NO)。这种气态的自由基分子调节着大量生物过程,从血压到免疫反应和神经信号级联反应。NO的过剩牵扯到一些疾病,包括老年痴呆,帕金森病和精神分裂症。因此nNOS抑制剂为这些疾病的治疗提供了一个潜在的治疗方法。但是因为一氧化氮合酶NOS存在内皮型NOS(eNOS)和诱导型NOS(iNOS)两种亚型,这使得nNOS抑制剂的治疗变得更为复杂。因此nNOS抑制剂的选择性是治疗发展的关键关注点。这篇综述探究了选择性nNOS抑制剂领域的最新进展,特别关注了用于具有更好药动性能的选择性nNOS配体的合理设计的计算方法。这些配体靶向于nNOS酶的4个关键结合点:四氢生物蝶呤,钙调蛋白,烟酰胺腺嘌呤二核苷酸磷酸(NADPH)和精氨酸的结合点。我们会依次介绍这些结合点和抑制它们的化合物以及应用于nNOS抑制领域的计算方法。
关键词: 结合袋,in silico,神经元一氧化氮合酶(nNOS),选择性抑制
Current Medicinal Chemistry
Title:Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations
Volume: 22 Issue: 21
Author(s): Adam M. Curtin, Gemma K. Kinsella and John C. Stephens
Affiliation:
关键词: 结合袋,in silico,神经元一氧化氮合酶(nNOS),选择性抑制
摘要: Neuronal nitric oxide synthase (nNOS) produces the key signalling mediator nitric oxide, (NO). This gaseous, free radical molecule modulates a vast array of biological processes, from vascular pressure to immune responses and neurological signalling cascades. Overproduction of NO has been implicated in conditions including Alzheimer’s disease, Parkinson’s disease and schizophrenia. Inhibition of nNOS therefore offers a potential therapeutic approach for treatment of these conditions. This endeavour is made more complex by the fact that there are two other isoforms of nitric oxide synthase (NOS), endothelial NOS (eNOS) and inducible NOS (iNOS). The selectivity of nNOS inhibitors is therefore a key concern for therapeutic development. This review explores recent advances in the field of selective nNOS inhibition. A particular focus is placed on computational approaches towards the rational design of selective nNOS ligands with improved pharmacokinetic properties. These ligands have been targeted at four key binding sites of the nNOS enzyme - the tetrahydrobiopterin, calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH) and arginine binding sites. The binding sites, and the compounds used to inhibit them, will be discussed in turn, along with the computational methods which have been employed in the field of nNOS inhibition.
Export Options
About this article
Cite this article as:
Adam M. Curtin, Gemma K. Kinsella and John C. Stephens , Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations, Current Medicinal Chemistry 2015; 22 (21) . https://dx.doi.org/10.2174/0929867322666150429112600
DOI https://dx.doi.org/10.2174/0929867322666150429112600 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spontaneous (Autoimmune) Chronic Urticaria in Children: Current Evidences, Diagnostic Pitfalls and Therapeutic Management
Recent Patents on Inflammation & Allergy Drug Discovery Human Immunodeficiency Virus (HIV) and Stroke: Targets for Intervention
Infectious Disorders - Drug Targets The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2
Current Drug Targets ABC Transporters and Drug Resistance in Patients with Epilepsy
Current Pharmaceutical Design Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design The Contribution of Transcriptomics to Biomarker Development in Systemic Vasculitis and SLE
Current Pharmaceutical Design Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry Cerebral Hypoperfusion During Carotid Artery Stenosis can Lead to Cognitive Deficits that may be Independent of White Matter Lesion Load
Current Neurovascular Research Current and Future Challenges in Primary Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry A Review of Eugenol-based Nanomedicine: Recent Advancements
Current Bioactive Compounds Targeting Leukocytes in Immune Glomerular Diseases
Current Medicinal Chemistry Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Resident Kidney Cells and Their Involvement in Glomerulonephritis
Current Drug Targets - Inflammation & Allergy